155 related articles for article (PubMed ID: 2303676)
1. Frequency of gastroduodenal lesions in asymptomatic patients on chronic aspirin or nonsteroidal antiinflammatory drug therapy.
Jaszewski R
J Clin Gastroenterol; 1990 Feb; 12(1):10-3. PubMed ID: 2303676
[TBL] [Abstract][Full Text] [Related]
2. Effect of anti-inflammatory drug administration in patients with rheumatoid arthritis. An endoscopic assessment.
Morris AD; Holt SD; Silvoso GR; Hewitt J; Tatum W; Grandione J; Butt JH; Ivey KJ
Scand J Gastroenterol Suppl; 1981; 67():131-5. PubMed ID: 6941392
[TBL] [Abstract][Full Text] [Related]
3. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions.
Dammann HG; Burkhardt F; Wolf N
Aliment Pharmacol Ther; 1999 Aug; 13(8):1109-14. PubMed ID: 10468689
[TBL] [Abstract][Full Text] [Related]
4. Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and enteric-coated aspirin.
Jaszewski R; Calzada R; Dhar R
Dig Dis Sci; 1989 Sep; 34(9):1361-4. PubMed ID: 2766902
[TBL] [Abstract][Full Text] [Related]
5. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy.
Silvoso GR; Ivey KJ; Butt JH; Lockard OO; Holt SD; Sisk C; Baskin WN; Mackercher PA; Hewett J
Ann Intern Med; 1979 Oct; 91(4):517-20. PubMed ID: 314764
[TBL] [Abstract][Full Text] [Related]
6. Clinical endoscopic evaluation of the gastroduodenal tolerance to (R)- ketoprofen, (R)- flurbiprofen, racemic ketoprofen, and paracetamol: a randomized, single-blind, placebo-controlled trial.
Jerussi TP; Caubet JF; McCray JE; Handley DA
J Clin Pharmacol; 1998 Feb; 38(2S):19S-24S. PubMed ID: 9549655
[TBL] [Abstract][Full Text] [Related]
7. Predictors of gastroduodenal erosions in patients taking low-dose aspirin.
Hart J; Hawkey CJ; Lanas A; Naesdal J; Talley NJ; Thomson AB; Yeomans ND
Aliment Pharmacol Ther; 2010 Jan; 31(1):143-9. PubMed ID: 19709095
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man.
Hoftiezer JW; Silvoso GR; Burks M; Ivey KJ
Lancet; 1980 Sep; 2(8195 pt 1):609-12. PubMed ID: 6107406
[TBL] [Abstract][Full Text] [Related]
9. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study.
Chowdhury A; Ganguly G; Chowdhury D; Santra A; Gupta JD; Roy T
Indian J Gastroenterol; 2001; 20(6):227-9. PubMed ID: 11817775
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspirin therapy.
Lockard OO; Ivey KJ; Butt JH; Silvoso GR; Sisk C; Holt S
Gastrointest Endosc; 1980 Feb; 26(1):5-7. PubMed ID: 6965646
[TBL] [Abstract][Full Text] [Related]
11. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial.
Feldman M; Cryer B; Mallat D; Go MF
Am J Gastroenterol; 2001 Jun; 96(6):1751-7. PubMed ID: 11419825
[TBL] [Abstract][Full Text] [Related]
12. Macroscopic small bowel mucosal injury caused by chronic nonsteroidal anti-inflammatory drugs (NSAID) use as assessed by capsule endoscopy.
Caunedo-Alvarez A; Gómez-Rodríguez BJ; Romero-Vázquez J; Argüelles-Arias F; Romero-Castro R; García-Montes JM; Pellicer-Bautista FJ; Herrerías-Gutiérrez JM
Rev Esp Enferm Dig; 2010 Feb; 102(2):80-5. PubMed ID: 20361843
[TBL] [Abstract][Full Text] [Related]
13. [Aspirin and gastroduodenal toxicity. A double-blind endoscopic study of the effects of placebo, aspirin and lysine acetylsalicylate in healthy subjects].
Bretagne JF; Feuillu A; Gosselin M; Gastard J
Gastroenterol Clin Biol; 1984 Jan; 8(1):28-32. PubMed ID: 6698337
[TBL] [Abstract][Full Text] [Related]
14. Gastroduodenal effects of nonsteroidal antiinflammatory drugs.
Kimmey MB
Postgrad Med; 1989 Apr; 85(5):65-70, 73. PubMed ID: 2648379
[No Abstract] [Full Text] [Related]
15. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use.
Larkai EN; Smith JL; Lidsky MD; Graham DY
Am J Gastroenterol; 1987 Nov; 82(11):1153-8. PubMed ID: 3499815
[TBL] [Abstract][Full Text] [Related]
16. Is Helicobacter pylori infection a risk or protective factor for mucosal lesions development in patients chronically treated with acetylsalicylic acid?
Kordecki H; Kurowski M; Kosik R; Pilecka D
J Physiol Pharmacol; 1997 Sep; 48 Suppl 4():85-91. PubMed ID: 9440059
[TBL] [Abstract][Full Text] [Related]
17. [Misoprostol in the prevention of gastric erosions caused by nonsteroidal anti-inflammatory agents].
Delmas PD; Lambert R; Capron MH
Rev Rhum Ed Fr; 1994 Feb; 61(2):126-31. PubMed ID: 7920500
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled, 6-day evaluation of two doses of misoprostol in gastroduodenal mucosal protection against damage from aspirin and effect on bowel habits.
Lanza FL; Kochman RL; Geis GS; Rack EM; Deysach LG
Am J Gastroenterol; 1991 Dec; 86(12):1743-8. PubMed ID: 1962619
[TBL] [Abstract][Full Text] [Related]
19. The effect of 15(R)-15-methyl prostaglandin E2 (Arbacet) on the healing of aspirin or nonsteroidal antiinflammatory drug-induced gastric mucosal lesions: an endoscopic study.
Jaszewski R; Crane SA
Am J Gastroenterol; 1987 Dec; 82(12):1271-4. PubMed ID: 3318402
[TBL] [Abstract][Full Text] [Related]
20. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Goldstein JL; Huang B; Amer F; Christopoulos NG
Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
